Alternative splicing dysregulation in pancreatic neuroendocrine tumors: splicing factor CELF4 is upregulated in PanNETs and is associated with aggressiveness
Ricardo Blázquez‐Encinas(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raquel Serrano‐Blanch(Instituto Maimónides de Investigación Biomédica de Córdoba), María Ángeles Gálvez-Moreno(Instituto Maimónides de Investigación Biomédica de Córdoba), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Emilia Alors‐Pérez(Instituto de Salud Carlos III), Sergio Pedraza‐Arévalo(Instituto Maimónides de Investigación Biomédica de Córdoba), Aura D. Herrera‐Martínez(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 0
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
|Cancer Letters|2015|91
Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches
|Clinical Cancer Research|2013|89